No Data
Mediwound's Promising Outlook: Expansion and Trials Support Buy Rating
MediWound Advances With FDA Approval and New Funding
MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate
MediWound | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Flash (MDWD) MEDIWOUND Posts Q3 Revenue $4.4M, Vs. Street Est of $6.0M
MediWound Sees FY24 Rev $20M >MDWD